Related Experiment Videos
Solid and hematologic malignancies in 60 patients with systemic mast cell disease.
W D Travis1, C Y Li, E J Bergstralh
1Section of Laboratory Hematology, Mayo Clinic, Rochester, Minn.
Archives of Pathology & Laboratory Medicine
|April 1, 1989
Summary
Systemic mast cell disease (SMCD) patients frequently develop malignancies, often preceding SMCD diagnosis. However, SMCD does not increase the risk of developing malignancies later, with hematologic cancers primarily affecting myeloid cells.
Area of Science:
- Hematology
- Oncology
- Mast Cell Biology
Background:
- The link between systemic mast cell disease (SMCD) and cancer is known but not fully understood.
- Investigating the temporal relationship and cancer risk in SMCD patients is crucial.
Purpose of the Study:
- To examine the chronological relationship between SMCD and malignancy onset.
- To determine if SMCD patients face an elevated risk of developing malignancies.
- To analyze the distribution of solid versus hematologic malignancies in SMCD patients.
Main Methods:
- Retrospective analysis of 19 malignancies in 17 out of 60 SMCD patients.
- Categorization of malignancies into solid tumors and hematologic types.
- Statistical evaluation of malignancy risk post-SMCD diagnosis.
Main Results:
- Most malignancies (13/17) were diagnosed before or within 12 months of SMCD.
- No increased risk of malignancy was found subsequent to SMCD diagnosis.
- Solid tumors showed random distribution; hematologic malignancies predominantly involved myeloid cells.
Conclusions:
- Malignancies often precede SMCD diagnosis.
- SMCD diagnosis does not elevate subsequent cancer risk.
- Hematologic malignancies in SMCD patients show a predilection for myeloid cell involvement.